Upon completion of this activity, the learners should be able to:
– Identify how current and emerging therapies target the complement pathway in patients with PNH
– Outline the safety and efficacy of new and emerging therapies for PNH
– Associate potential clinical impact of emerging therapies in addressing limitations of current treatments in patients with PNH.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 0.5 credits
MOC types
ABIM — Medical KnowledgeUp to 0.5 points
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Specialties served/covered
- Anatomic & Clinical Pathology
- Blood Banking & Transfusion Medicine
- General Internal Medicine
- Hematology
- Hematopathology
- Medical Oncology
- Musculoskeletal Oncology
- Pediatric Hematology-Oncology
- Pediatric Transplant Hepatology
- GI & Liver
- Internal Medicine
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
-
ReleasedNov 10, 2023
-
Last day to claim creditNov 10, 2026 4 weeks left
-
American Society of Hematology ADVANCES IN THE THERAPEUTIC MANAGEMENT OF PNH II: Getting to Know PNH
-
American Society of Hematology ADVANCES IN THE THERAPEUTIC MANAGEMENT OF PNH I: Understanding PNH and Other Complement-mediated Hematologic Disorders
-
American Society of Hematology Addressing Unmet Needs in Myelofibrosis Management III: Current and Emerging JAK Inhibitors
-
touchIME, USF Health Evolving Paradigms in PNH Management: Interpreting the Latest Data
-
PRIME Education, Inc. (PRIME®) Changing Paradigms in Paroxysmal Nocturnal Hemoglobinuria: Understanding New Pathways, Clinical Evidence, and Practice Guidelines
-
Medscape, LLC Keeping Current in the Complement Conversation: Expert Insights on Key Developments in IgA Nephropathy
